AZTherapies - Harnessing the Power of Neuro-Immunology

A NEW APPROACH TO FIGHT NEURODEGENERATIVE DISEASES

AZTherapies is an advanced clinical-stage biopharmaceutical company developing novel therapies that aim to fundamentally change neurodegenerative disease progression, extending normal cognition and function and improving quality of life in the aging population.

The AZTherapies team shares a practical, innovative, entrepreneurial, and mission-driven approach to bringing therapeutics to patients more quickly, safely, and affordably.

Advancing a growing pipeline of candidates to treat patients with few therapeutic options, our lead program, ALZT-OP1, is built on a multi-modal approach that recognizes neuroinflammation as a root cause of serious neurodegeneration and seeks to stop or slow the progression of disease. Our Phase 3 COGNITE trial in early Alzheimer’s disease completed in late 2020. Following our lead program, we are advancing candidates for the treatment of amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases.

AZTherapies is a private company headquartered in Boston, Massachusetts.

AZTherapies At A Glance

BREAKTHROUGH SCIENCE

Neuroinflammatory mechanism that changes the activation state of microglial brain immune cells from an aggressive, pro-inflammatory state to an anti-inflammatory, neuroprotective state.

EXECUTION

Completed trial of a novel drug combination in early Alzheimer’s Disease. Phase 2a study in patients with mild to moderate ALS. Next-generation compound pre-IND.

PATENT PORTFOLIO

More than 100 patents & pending applications claiming novel compositions of matter, formulation, manufacturing and device/delivery for numerous neurodegenerative and other indications.

PIPELINE

Multiple follow-on programs with potential to treat and slow the progression of neurodegenerative diseases, while improving the quality of life of the aging population.